Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CCM.0000000000003498 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Barriers to medication administration error reporting in a tertiary hospital in Lebanon.
BMJ Open Qual
December 2024
School of Medicine, Saint Joseph University School of Medical Science, Beirut, Lebanon.
Objective: The aim of this study is to identify the key barriers that prevent medication administration errors (MAEs) from being reported by nurses in Lebanese hospitals.
Methods: A quantitative cross-sectional study was conducted at Hotel-Dieu de France Hospital using a self-administered questionnaire. A total of 275 responses were recorded and analysed using the IBM SPSS software V.
Room-Temperature CsPbI-Quantum-Dot Reinforced Solid-State Li-Polymer Battery.
Small
January 2025
Key Laboratory of Advanced Technologies of Materials, Ministry of Education, School of Materials Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, China.
A novel polymer electrolyte based on CsPbI quantum dots (QDs) reinforced polyacrylonitrile (PAN), named as PIL, is exploited to address the low room-temperature (RT) ion conductivity and poor interfacial compatibility of polymer solid-state electrolytes. After optimizing the content of CsPbI QDs, RT ion conductivity of PIL largely increased from 0.077 to 0.
View Article and Find Full Text PDFBeyond Longer Intervals: Advocating for Regular Treatment of Neovascular AMD.
J Clin Med
December 2024
Division of Ophthalmology, Department of Surgery, UMass Chan-Lahey School of Medicine, Burlington, MA 01805, USA.
Personalizing the management of neovascular age-related macular degeneration (nAMD) poses significant challenges for practicing retina specialists and their patients. This commentary addresses some of these complexities, particularly those that arise in the context of an expanding array of intravitreal agents targeting vascular endothelial growth factor (VEGF) and related retinal disease targets. Many of these newer agents approved by the Food and Drug Administration (FDA) for the treatment of nAMD have labeling that indicates that they can provide non-inferior visual outcomes when compared head-to-head with previously available treatments and can be used at significantly extended dosing intervals in some patients.
View Article and Find Full Text PDFResearch on Mine-Personnel Helmet Detection Based on Multi-Strategy-Improved YOLOv11.
Sensors (Basel)
December 2024
School of Coal Engineering, Shanxi Datong University, Datong 037000, China.
In the complex environment of fully mechanized mining faces, the current object detection algorithms face significant challenges in achieving optimal accuracy and real-time detection of mine personnel and safety helmets. This difficulty arises from factors such as uneven lighting conditions and equipment obstructions, which often lead to missed detections. Consequently, these limitations pose a considerable challenge to effective mine safety management.
View Article and Find Full Text PDFChronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors.
Cancers (Basel)
January 2025
Department of Hematology, Hull University Teaching Hospitals NHS Trust, Hull HU3 2JZ, UK.
Chronic lymphocytic leukemia (CLL) treatment has undergone a significant evolution with a shift from historical chemotherapeutic regimens to targeted therapies such as Bruton tyrosine kinase (BTK) and BCL-2 inhibitors. These advancements have been associated with a notable improvement in survival rates with a transformation of CLL into a chronic and manageable condition for most persons with this disease. However, as a consequence of improved outcomes, long-term CLL survivors now face emergent challenges which include a risk of infections, cardiovascular complications, and secondary malignancies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!